Abbott at ESC 2015: Absorb Now Standing Up Against Xience, But Time To Shine Would Come Later
This article was originally published in Clinica
Data from two separate clinical trials pitting Abbott’s Absorb bioresorbable heart stent against the company’s Xience everolimus drug-eluting stent have shown comparable clinical outcomes for both technologies. But these are still early days, and the real benefits of Absorb will only be known over the longer term.
Register for our free email digests: